AU2002251624B8 - Novel compound for treatment of allergy and asthma - Google Patents

Novel compound for treatment of allergy and asthma Download PDF

Info

Publication number
AU2002251624B8
AU2002251624B8 AU2002251624A AU2002251624A AU2002251624B8 AU 2002251624 B8 AU2002251624 B8 AU 2002251624B8 AU 2002251624 A AU2002251624 A AU 2002251624A AU 2002251624 A AU2002251624 A AU 2002251624A AU 2002251624 B8 AU2002251624 B8 AU 2002251624B8
Authority
AU
Australia
Prior art keywords
ige
human
fab
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002251624A
Other languages
English (en)
Other versions
AU2002251624A2 (en
AU2002251624B2 (en
AU2002251624A1 (en
Inventor
Jonas Adriansson
Hans Gronlund
Erik Hogbom
Dietrich Kraft
Sylvia Laffer
Kenneth H. Roux
Wolfgang R. Sperr
Peter Valent
Rudolf Valenta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Phadia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia AB filed Critical Phadia AB
Publication of AU2002251624A1 publication Critical patent/AU2002251624A1/en
Assigned to PHADIA AB reassignment PHADIA AB Request for Assignment Assignors: PHARMACIA DIAGNOSTICS AB
Publication of AU2002251624A2 publication Critical patent/AU2002251624A2/en
Application granted granted Critical
Publication of AU2002251624B2 publication Critical patent/AU2002251624B2/en
Publication of AU2002251624B8 publication Critical patent/AU2002251624B8/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002251624A 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma Expired AU2002251624B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma
SE0101093-3 2001-03-28
PCT/SE2002/000636 WO2002079257A1 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma

Publications (4)

Publication Number Publication Date
AU2002251624A1 AU2002251624A1 (en) 2003-04-03
AU2002251624A2 AU2002251624A2 (en) 2008-05-01
AU2002251624B2 AU2002251624B2 (en) 2008-09-04
AU2002251624B8 true AU2002251624B8 (en) 2008-10-02

Family

ID=20283563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251624A Expired AU2002251624B8 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma

Country Status (7)

Country Link
US (2) US6986889B2 (enExample)
EP (1) EP1373322A1 (enExample)
JP (2) JP2005500992A (enExample)
AU (1) AU2002251624B8 (enExample)
CA (1) CA2441048C (enExample)
SE (1) SE0101093D0 (enExample)
WO (1) WO2002079257A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884877B2 (en) 2001-10-03 2005-04-26 Florida State University Research Foundation, Inc. Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
JP2025533898A (ja) * 2022-10-07 2025-10-09 アブウィズ バイオ，インコーポレイテッド 抗ｉｇｅ抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625039A (en) * 1991-12-24 1997-04-29 Snow Brand Milk Products Co., Ltd. Anti-human IgE monoclonal antibodies
WO2000063252A1 (en) * 1999-04-14 2000-10-26 Novartis Ag Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
WO2000072879A1 (en) 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625039A (en) * 1991-12-24 1997-04-29 Snow Brand Milk Products Co., Ltd. Anti-human IgE monoclonal antibodies
WO2000063252A1 (en) * 1999-04-14 2000-10-26 Novartis Ag Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDOLF, et al. The Journal of Immunology (2000), 165, 813-819 *

Also Published As

Publication number Publication date
JP2014012683A (ja) 2014-01-23
CA2441048A1 (en) 2002-10-10
SE0101093D0 (sv) 2001-03-28
CA2441048C (en) 2011-12-13
US6986889B2 (en) 2006-01-17
AU2002251624A2 (en) 2008-05-01
US20030035796A1 (en) 2003-02-20
EP1373322A1 (en) 2004-01-02
WO2002079257A1 (en) 2002-10-10
USRE42324E1 (en) 2011-05-03
AU2002251624B2 (en) 2008-09-04
JP2005500992A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
JP6841449B2 (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
JP3925663B2 (ja) 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
Flicker et al. Conversion of grass pollen allergen‐specific human IgE into a protective IgG1 antibody
JP6225189B2 (ja) ヒト膵島アミロイドポリペプチド（ｈＩＡＰＰ）特異的抗体およびその使用
Flicker et al. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity
CA2074089C (en) Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP2011042654A (ja) 新規のＩｇＥエピトープの同定
JP2003231696A (ja) ペプチド免疫原
JP2009046497A (ja) Ａβペプチドを隔離するヒト化抗体
JPWO1997002290A1 (ja) 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
EP0585224A1 (en) MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
US20040198961A1 (en) Fce fusion proteins for treatment of allergy and asthma
AU2003293096A1 (en) Humanized antibodies against monocyte chemotactic proteins
USRE42324E1 (en) Compound for treatment of allergy and asthma
JP2004357712A (ja) 免疫グロブリンイソタイプに対する再形状化されたモノクローナル抗体
KR101365375B1 (ko) 신규한 ＩｇＥ 에피토프의 확인
JPH10509948A (ja) Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
Laffer et al. A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcϵRI interaction and reacts with receptor-bound IgE
AU2002251624A1 (en) Novel compound for treatment of allergy and asthma
Levy et al. Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA.
Lupinek et al. Trimolecular complex formation of IgE, FcεRI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE
JP2022172170A5 (enExample)
AU2018205484B2 (en) Therapeutic anti-lgE antibodies and methods and compositions thereof
EP2258727A1 (en) Immunoglobulin preparation for the treatment of autoimmune diseases and immune system disorders
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: PHADIA AB

Free format text: FORMER NAME: PHARMACIA DIAGNOSTICS AB

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 MAR 2008

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE HAS BEEN EXTENDED TO 28 AUG 2008.

TH Corrigenda

Free format text: IN VOL 22, NO 35, PAGE(S) 4205 UNDER THE HEADING APPLICATIONS ACCEPTED -NAME INDEX UNDER THE NAME PHADIA AB, APPLICATION NO. 2002251624, UNDER INID (72), CORRECT THE NAME OF THE CO-INVENTOR TO VALENTA, RUDOLF

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired